{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,2]],"date-time":"2026-06-02T14:42:08Z","timestamp":1780411328307,"version":"3.54.1"},"reference-count":24,"publisher":"Wiley","issue":"9","license":[{"start":{"date-parts":[[2007,9,11]],"date-time":"2007-09-11T00:00:00Z","timestamp":1189468800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cancer"],"published-print":{"date-parts":[[2007,11]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>BACKGROUND.<\/jats:title><jats:p>Interferon\u2010alpha (IFN\u2010\u03b1) has shown significant activity in the treatment of BCR\u2010ABL\u2013negative myeloproliferative disorders (MPDs), particularly essential thrombocythemia (ET) and polycythemia vera (PV). PEG\u2010IFN\u2010\u03b1\u20102b is a pegylated IFN\u2010\u03b1\u20102b with a significant advantage over nonpegylated form in that it is administered once a week.<\/jats:p><\/jats:sec><jats:sec><jats:title>METHODS.<\/jats:title><jats:p>Thirty\u2010eight patients with BCR\u2010ABL\u2013negative MPDs were treated with PEG\u2010IFN\u2010\u03b1\u20102b, given subcutaneously weekly, at the starting dose of 3 \u03bcg\/kg\/wk for the first 14 patients and then 2 \u03bcg\/kg\/wk for the next 24 patients, with intent to treat patients as long as they benefited from the therapy.<\/jats:p><\/jats:sec><jats:sec><jats:title>RESULTS.<\/jats:title><jats:p>Median age was 54 years. Patient diagnoses were: 13 (34%) ET; 11 (29%) primary myelofibrosis (PMF); 5 (13%) BCR\u2010ABL\u2013negative chronic myeloid leukemia (CML); 4 (10.5%) hypereosinophilic syndrome (HES); 4 (10.5%) PV; and 1 (3%) unclassified myeloproliferative disease (uMPD). Recorded grade 3\u20134 toxicities were related to fatigue, myelosuppression, and musculoskeletal pain. Ten (26%) patients stopped treatment because of toxicity. Thirteen (34%) patients achieved a complete remission, and 4 (11%) achieved a partial response. Only 1 patient with PMF responded. Median time to response was 5 months. Median duration of response was 20 months. Three patients had a sustained response for &gt;24 months.<\/jats:p><\/jats:sec><jats:sec><jats:title>CONCLUSIONS.<\/jats:title><jats:p>PEG\u2010IFN\u2010\u03b1\u20102b, with proper dose modifications, is effective in controlling disease in a significant proportion of BCR\u2010ABL\u2013negative MPD patients, particularly ET and PV. However, toxicities encountered with PEG\u2010IFN\u2010\u03b1\u20102b therapy are similar to those obtained with conventional IFN\u2010\u03b1, thus limiting the duration of therapy. Cancer 2007. \u00a9 2007 American Cancer Society.<\/jats:p><\/jats:sec>","DOI":"10.1002\/cncr.23018","type":"journal-article","created":{"date-parts":[[2007,9,11]],"date-time":"2007-09-11T14:18:45Z","timestamp":1189520325000},"page":"2012-2018","source":"Crossref","is-referenced-by-count":107,"title":["PEG\u2010IFN\u2010\u03b1\u20102b therapy in BCR\u2010ABL\u2013negative myeloproliferative disorders"],"prefix":"10.1002","volume":"110","author":[{"given":"Elias","family":"Jabbour","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hagop","family":"Kantarjian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jorge","family":"Cortes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Deborah","family":"Thomas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guillermo","family":"Garcia\u2010Manero","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alessandra","family":"Ferrajoli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefan","family":"Faderl","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mary Ann","family":"Richie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Miloslav","family":"Beran","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francis","family":"Giles","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Srdan","family":"Verstovsek","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2007,10,18]]},"reference":[{"key":"e_1_2_5_2_2","doi-asserted-by":"publisher","DOI":"10.4065\/80.9.1220"},{"key":"e_1_2_5_3_2","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.22026"},{"key":"e_1_2_5_4_2","doi-asserted-by":"publisher","DOI":"10.1002\/(SICI)1097-0142(19980915)83:6<1205::AID-CNCR21>3.0.CO;2-8"},{"key":"e_1_2_5_5_2","article-title":"Persistence of remission of myeloid metaplasia after treatment with recombinant interferon alpha\u20102b [abstract]","volume":"72","author":"Gilbert HS","year":"1988","journal-title":"Blood."},{"key":"e_1_2_5_6_2","article-title":"Regression of myeloid metaplasia during IFN\u2010alpha\u20102b treatment of myeloproliferative disease is accompanied by reduction in circulating concentrations of colony\u2010stimulating factor\u20101 [abstract]","volume":"37","author":"Gilbert HS","year":"1989","journal-title":"Clin Res."},{"key":"e_1_2_5_7_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(88)90664-2"},{"key":"e_1_2_5_8_2","doi-asserted-by":"publisher","DOI":"10.1089\/107999001317205240"},{"key":"e_1_2_5_9_2","doi-asserted-by":"publisher","DOI":"10.1021\/bi000617t"},{"key":"e_1_2_5_10_2","doi-asserted-by":"publisher","DOI":"10.1053\/jhep.2000.16661"},{"key":"e_1_2_5_11_2","doi-asserted-by":"publisher","DOI":"10.2165\/00003495-200161150-00013"},{"key":"e_1_2_5_12_2","doi-asserted-by":"publisher","DOI":"10.2165\/00063030-200115070-00001"},{"key":"e_1_2_5_13_2","doi-asserted-by":"publisher","DOI":"10.1053\/jhep.2001.26371"},{"key":"e_1_2_5_14_2","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.21086"},{"key":"e_1_2_5_15_2","doi-asserted-by":"publisher","DOI":"10.1007\/s00280-002-0533-4"},{"key":"e_1_2_5_16_2","first-page":"1333","article-title":"Pegylated interferon for the treatment of high risk essential thrombocythemia: results of a phase II study","volume":"90","author":"Langer C","year":"2005","journal-title":"Haematologica."},{"key":"e_1_2_5_17_2","doi-asserted-by":"crossref","DOI":"10.1182\/blood.V106.11.2600.2600","article-title":"PEG intron treatment in 90 patients with essential thrombocythemia (ET) final report of a phase II study [abstract]","volume":"106","author":"Gugliotta L","year":"2005","journal-title":"Blood."},{"key":"e_1_2_5_18_2","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.21900"},{"key":"e_1_2_5_19_2","doi-asserted-by":"publisher","DOI":"10.1038\/sj.leu.2403217"},{"key":"e_1_2_5_20_2","doi-asserted-by":"publisher","DOI":"10.1055\/s-2006-942761"},{"key":"e_1_2_5_21_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2006-03-009860"},{"key":"e_1_2_5_22_2","doi-asserted-by":"crossref","DOI":"10.1182\/blood.V108.11.670.670","article-title":"Peg IFN\u03b1\u20102a in polycythemia vera (PV). Results of a phase 2 study by the French \u201cPV\u2010NORD\u201d group [abstract]","volume":"108","author":"Kiladjian JJ","year":"2006","journal-title":"Blood."},{"key":"e_1_2_5_23_2","doi-asserted-by":"crossref","DOI":"10.1182\/blood.V108.11.4884.4884","article-title":"Treatment with pegylated interferon\u2010alpha\u20102\u00aa (PEG\u2010IFN\u2010\u03b1\u20102a; PEGASYS\u2122) for patients with essential thrombocythemia (ET) and polycythemia vera (PV) [abstract]","volume":"108","author":"Quintas\u2010Cardama A","year":"2006","journal-title":"Blood."},{"key":"e_1_2_5_24_2","first-page":"1281","article-title":"Limited effects on JAK2 mutational status after pegylated interferon alpha\u20102b therapy in polycythemia vera and essential thrombocythemia","volume":"91","author":"Samuelsson J","year":"2006","journal-title":"Haematologica."},{"key":"e_1_2_5_25_2","doi-asserted-by":"publisher","DOI":"10.1080\/10428190601175393"}],"container-title":["Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fcncr.23018","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/acsjournals.onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/cncr.23018","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,12]],"date-time":"2025-10-12T14:20:58Z","timestamp":1760278858000},"score":1,"resource":{"primary":{"URL":"https:\/\/acsjournals.onlinelibrary.wiley.com\/doi\/10.1002\/cncr.23018"}},"subtitle":["Final Result of a Phase 2 Study"],"short-title":[],"issued":{"date-parts":[[2007,10,18]]},"references-count":24,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2007,11]]}},"alternative-id":["10.1002\/cncr.23018"],"URL":"https:\/\/doi.org\/10.1002\/cncr.23018","archive":["Portico"],"relation":{},"ISSN":["0008-543X","1097-0142"],"issn-type":[{"value":"0008-543X","type":"print"},{"value":"1097-0142","type":"electronic"}],"subject":[],"published":{"date-parts":[[2007,10,18]]}}}